Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects"

Circulation

Volumn 122, Issue 4, 2010, Pages 370-378

  Mohammed, Selma F ^a   Ohtani, Tomohito ^a   Korinek, Josef ^a   Lam, Carolyn S P ^a   Larsen, Katarina ^a   Simari, Robert D ^a   Valencik, Maria L ^b   Burnett, John C ^a   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

deoxycorticosterone acetate; heart failure; hypertrophy; mineralocorticoids; stress; ventricular ejection fraction

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOLOGY; HYPERTENSION; INFLAMMATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALDOSTERONE; ANIMALS; ATRIAL NATRIURETIC FACTOR; CAPILLARIES; COLLAGEN; CYTOCHROME B GROUP; DESOXYCORTICOSTERONE; HEART FAILURE; INFLAMMATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED STRAINS; MINERALOCORTICOIDS; NADPH OXIDASE; OSTEOPONTIN; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 77955172275     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.915215     Document Type: Article

References (46)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
2. Redfield MM. Understanding. "diastolic" heart failure. N Engl J Med. 2004;350:1930-1931.
3. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761.
4. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
5. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol. 2007;292:R946-R954.
6. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation. 2003;108:1831-1838.
7. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427.
8. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1-20.
9. Funder JW. Why are mineralocorticoid receptors so nonselective? Curr Hypertens Rep. 2007;9:112-116.
10. 2 in peripheral blood mononuclear cells. Circulation. 2005;111: 51-57.
11. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988; 242:583-585.
12. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275.
13. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995; 92:175-182.
14. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
15. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res. 1992;26:671-677.
16. Kitagawa H, Yanagisawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, Nagasawa H, Nakajima T, Matsumoto T, Kato S. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol. 2002;22: 3698-3706.
17. Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol. 2005;19:2211-2221.
18. Skott O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL. Rapid actions of aldosterone in vascular health and disease: friend or foe? Pharmacol Ther. 2006;111:495-507.
19. Weber KT, Sun Y, Wodi LA, Munir A, Jahangir E, Ahokas RA, Gerling IC, Postlethwaite AE, Warrington KJ. Toward a broader understanding of aldosterone in congestive heart failure. J Renin Angiotensin Aldosterone Syst. 2003;4:155-163.
20. Zhang Q, Piston DW, Goodman RH. Regulation of corepressor function by nuclear NADH. Science. 2002;295:1895-1897.
21. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005;93:121-125.
22. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003;285:H1261-H1269.
23. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension. Circulation. 1991;83:1676-1684.
24. Shimizu G, Zile MR, Blaustein AS, Gaasch WH. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. Circulation. 1985;71:266-272.
25. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54:410-418.
26. Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999;100:2443-2448.
27. Lohmeier TE, Davis JO. Renin-angiotensin-aldosterone system in experimental renal hypertension in the rabbit. Am J Physiol. 1976;230: 311-318.
28. Weber KT. Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms. Curr Heart Fail Rep. 2004;1:51-56.
29. Grossmann C, Freudinger R, Mildenberger S, Husse B, Gekle M. EF domains are sufficient for nongenomic mineralocorticoid receptor actions. J Biol Chem. 2008;283:7109-7116.
30. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intra-cellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
31. Mihailidou AS, Mardini M, Funder JW. Rapid, nongenomic effects of aldo-sterone in the heart mediated by epsilon protein kinase C. Endocrinology. 2004;145:773-780.
32. Mochly-Rosen D, Wu G, Hahn H, Osinska H, Liron T, Lorenz JN, Yatani A, Robbins J, Dorn GW II. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res. 2000;86:1173-1179.
33. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res. 2000;86:1218-1223.
34. Costello-Boerrigter LC, Boerrigter G, Harty GJ, Cataliotti A, Redfield MM, Burnett JC Jr. Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension. 2007; 50:481-488.
35. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC Jr, Redfield MM. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289-295.
36. Miura R, Nakamura K, Miura D, Miura A, Hisamatsu K, Kajiya M, Hashimoto K, Nagase S, Morita H, Fukushima Kusano K, Emori T, Ishihara K, Ohe T. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Sci. 2006;102: 288-295. (Pubitemid 44790690)
37. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res. 2004; 64:24-31.
38. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, Minami I, Iwashima F, Sakai H, Tateno T, Sato R, Hirata Y. Aldo-sterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun. 2005;336:163-167.
39. Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev. 2005;10:47-52.
40. Armanini D, Fiore C, Calo LA. Mononuclear leukocyte mineralocor-ticoid receptors: a possible link between aldosterone and atherosclerosis. Hypertension. 2006;47:e4.
41. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871-878.
42. Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci. 2008;335:105-110.
43. Selektor Y, Weber KT. The salt-avid state of congestive heart failure revisited. Am J Med Sci. 2008;335:209-218.
44. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290:H286-H294.
45. Losel RM, Feuring M, Falkenstein E, Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids. 2002;67: 493-498.
46. Bhargava A, Fullerton MJ, Myles K, Purdy TM, Funder JW, Pearce D, Cole TJ. The serum-and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology. 2001;142:1587-1594.